Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Mã chứng khoánAQST
Tên công tyAquestive Therapeutics Inc
Ngày IPOJul 25, 2018
Giám đốc điều hànhMr. Daniel Barber
Số lượng nhân viên142
Loại chứng khoánOrdinary Share
Kết thúc năm tài chínhJul 25
Địa chỉ30 Technology Dr
Thành phốWARREN
Sàn giao dịch chứng khoánNASDAQ Global Market Consolidated
Quốc giaUnited States of America
Mã bưu điện07059-5166
Điện thoại19089411900
Trang webhttps://aquestive.com/
Mã chứng khoánAQST
Ngày IPOJul 25, 2018
Giám đốc điều hànhMr. Daniel Barber
Tổng cộng
0.00
USD đã được phân phối dưới dạng cổ tức trong 5 năm qua.

Không có dữ liệu